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1. INTRODUCTION 
 
1.1. Lung anatomy 
 
The respiratory system can be anatomically divided into two regions: conducting and 
respiratory. The conducting airways consist of the air-transmitting passages 
of the nose, nasopharynx, larynx, trachea, bronchi and bronchioles (Gray 1918, 2000; 
Itoh, Nishino et al. 2004) the latter three of which form the tracheo-bronchial region 
of the lung (generations 1-16 in the bifurcating airway model; Figure 1). The actual 
exchange of gases (i.e., fresh oxygen into and carbon dioxide out of the body) occurs 
across the distal lung respiratory epithelium comprised of the alveolar ducts and 
saccules (i.e., the alveoli, generations 17-23 in the bifurcating airway model; Figure 
1). 
 
 
The primary function of the conducting airways is to act as conduit for air 
movement. Additionally, this region provides filtration, warming and humidification 
of inhaled air.  
Figure 1: Structure of the human respiratory tract, adapted from (Weibel 1963). 
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Specialised extra-pulmonary organs and tissues of the conducting system also serve 
other functions. For example, the nose provides a first-pass air filtration system, 
the pharynx aids in alimentation and the larynx is required for phonation (McDowell, 
Barrett et al. 1978). The cellular composition of the epithelium varies according 
to the airway generation (Table 1).  
 
Table 1: Cell types of the healthy respiratory epithelium 
 
Lung region Bronchi Bronchioles 
Terminal 
bronchioles 
Alveoli 
Type 
of epithelium 
Pseudostratified 
columnar 
Simple 
columnar 
Simple 
cuboidal 
Simple 
squamous 
Predominant 
cell types 
Basal  
Basal cell 
Kultschitzky cell 
Superficial 
Ciliated cell 
Brush cell 
Goblet cell 
Serous cell 
Mucous cell 
Ciliated cell 
Goblet cell 
 
Ciliated cell 
Clara cell 
Alveolar type 
I cell 
Alveolar type 
II cell 
 
 
The lining of the tracheo-bronchial airways is composed of several cell types 
including basal, goblet, ciliated, brush, serous, Clara, and neuroendocrine cells 
(Jeffery and Reid 1975). A variety of migratory cells such as lymphocytes, 
leukocytes, and mast cells are also present in the epithelium (Jeffery and Reid 1975). 
In the terminal bronchioles the epithelium is composed of ciliated cells and 
Clara cells (Plopper 1996). In the alveolar region epithelial type I and II cells and 
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alveolar macrophages are present (Plopper 1996). The squamous alveolar type I 
(ATI) cell covers approximately 96% of the alveolar surface area and has an average 
cell thickness of 0.26 µm (Stone, Mercer et al. 1992). About 3% of the alveolar 
surface is covered by the much smaller cuboidal alveolar type II (ATII) cells, which 
synthesise and secrete surface active materials (Mason and Crystal 1998). 
The heterogenous composition of the lung epithelium results in a large variation 
of tight junctional forms with variable tightness (Schneeberger 1980; Godfrey 1997). 
 
The lung and its luminal lining fluid are regularly exposed to a plethora 
of aerosolised compounds, which include drug molecules, and act as a barrier 
between air and the body. The lung, therefore, is in an ideal location and is 
frequently used to biotransform such compounds to reduce their potential toxicity. 
An important part of this biotransformation feature is the ability to efflux potentially 
harmful substances or their metabolites out of the body. On the other hand, 
absorption mechanisms are necessary for catabolic processes, for example, 
within the airspaces or to re-absorb endogenous compounds from the lining fluid 
(e.g., surfactant components, serum proteins and neurotransmitters). The respiratory 
epithelium forms a selective barrier against the entry of compounds into blood 
(Figure 2).  
 
Figure 2: Possible pathways across the lung epithelial barrier. 
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Figure 2 legend: (1) Absorption of compounds via the paracellular route is restricted 
by intercellular tight junctions. (2) Carrier-mediated mechanisms at the apical and/or 
basolateral membranes facilitate the transcellular absorption of certain compounds. 
(3) Efflux transporters at the apical membrane may actively drive compounds back 
into the lung lumen thus restricting their absorption into blood. (4) Apical efflux 
transporters may also facilitate the pulmonary clearance of compounds that are 
already present in blood. (5) Intracellular metabolising enzymes may modify 
compounds before they enter the blood. (6) Apical efflux transporters and 
intracellular metabolising enzymes may co-ordinately metabolise and excrete 
compounds, forming an effective barrier against pulmonary absorption. 
 
In the 1970‘s and 1980‘s, Schanker and co-workers conducted a series of studies 
on the disappearance rate of various compounds from rat lungs after intra-tracheal 
instillation and aerosol inhalation. Their studies showed that most compounds were 
absorbed by passive diffusion and that the rate of absorption increased with 
an increase in lipophilicity for compounds with partition coefficients 
in chloroform/buffer pH 7.4 ranging from -3 to 2 (Brown and Schanker 1983; 
Schanker and Hemberger 1983). Recently, systematic generation of in vitro and 
in vivo pharmacokinetic data on the absorption of drugs across the rat lung barrier 
after aerosol delivery has revealed that lipophilicity, molecular polar surface area, 
and hydrogen bonding potential are the most influential physicochemical properties 
for pulmonary absorption of structurally diverse, low molecular weight compounds 
with logD7.4 ranging from –4 to 3 (Tronde 2002). In contrast to the intestinal mucosa 
and the blood-brain barrier, the pulmonary epithelium was shown to be highly 
permeable to drugs with a high molecular polar surface area (Tronde 2002). 
 
Absorption of lipophilic compounds is generally considered to occur by membrane 
diffusion (Effros and Mason 1983) whereas hydrophilic solutes appear to be 
absorbed by passive diffusion through intercellular junction pores (Crystal 1991). 
Like hydrophilic molecules, most exogenous macromolecules with a molecular 
weight less than 40 kDa are also thought to be absorbed from the air space passive 
diffusion via the tight junctional pathway (Patton 1996; Bur, Huwer et al. 2006). 
The absorption rate of hydrophilic compounds is inversely related to their molecular 
weight (range 60-75 kDa) (Schanker and Burton 1976). However, for compounds 
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weighing less than 1 kDa, the effect of molecular weight on the absorption rate 
appears to be negligible (Niven 1992). Drug transporters such as peptide transporters 
(Groneberg, Eynott et al. 2002), P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP), multidrug resistance-related proteins (MRPs) (van der Deen, de 
Vries et al. 2005; Endter, Becker et al. 2007), and organic cation transporters (OCTs) 
(Ehrhardt, Kneuer et al. 2005; Horvath, Schmid et al. 2007) have been identified 
in the lung although a greater understanding of transporter impact on drug 
absorption from the lung is required. 
 
Clearly, whole animal studies cannot be used as a screening tool in the early stages 
of drug development. Therefore, cell culture models have been employed 
for permeability screening of new drug libraries that have been generated through 
combinatorial chemistry and high-throughput pharmacological screening (Artursson 
and Borchardt 1997). The development of screening models for the intestinal barrier 
started in the late 1980s (Hidalgo, Raub et al. 1989) and, a couple of years later, 
the first in vitro models became available for studies of pulmonary drug 
disposition (Mathias, Yamashita et al. 1996). 
 
1.2.Cell culture models for pulmonary drug disposition in vitro studies 
 
1.2.1. In vitro models of the tracheo-bronchial airspace 
1.2.1.1.Primary cell cultures 
 
Protocols for the isolation and culture of primary tracheo-bronchial epithelial cells 
obtained from the lungs of many species have been developed over the last 30 years. 
These include primary cultures of airway epithelial cells of the mouse (Oreffo, 
Morgan et al. 1990), hamster (Kaufman 1976), guinea pig (Robison, Dorio et al. 
1993), rat (Suda, Sato et al. 1995), ferret (Chung, Kercsmar et al. 1991), rabbit 
(Mathias, Kim et al. 2004), dog (Welsh 1985), pig (Black, Ghatei et al. 1989), cow 
(Sisson, Tuma et al. 1991), horse (Sime, McKellar et al. 1997) and human (de Jong, 
van Sterkenburg et al. 1993). Most of the protocols result in well-differentiated 
epithelial cells with mixed phenotypes and these primary cell cultures are generally 
good platforms for drug absorption studies for a couple of subcultures after which 
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they lose their
 
ability to form tight junctions and their ability to generate high 
transepithelial electrical resistance
 
(TEER) is lost. The degradation of these cultures 
is characterised by a linear drop in short-circuit current (Isc) which has been observed 
over successive passages in human tracheal epithelial cells in primary culture 
(Galietta, Lantero et al. 1998). These subcultures exhibited minimal rates of active 
Na
+
 and Cl
-
 transport by passage 3 and beyond passage 4 the cells failed to generate 
any active ion transport when studied using Ussing chamber techniques. These
 
data suggest that it is important to develop airway epithelial
 
cell lines that retain 
the ability to differentiate, form tight
 
junctions, and maintain ion channel/pump 
physiology when grown in vitro (Galietta, Lantero et al. 1998). 
 
Ready-to-use culture systems of human tracheo-bronchial cell layers exhibiting well-
differentiated ciliated and goblet cell phenotypes are commercially available 
(Epiairway system, Mattek Corporation, Ashland, MA, USA) (Chemuturi, Hayden 
et al. 2005). Although Epiairway is marketed for use in drug delivery studies, little 
data has been reported to date supporting this use perhaps reflecting low usage rate 
by pharmaceutical companies due to cost or efficacy, or lack of publication 
of Epiairway
TM
 use due to confidentiality constraints of the pharmaceutical industry. 
In general, primary culture is less convenient and economical than the use of cell 
lines. Hence, primary cultured tracheo-bronchial cell layers have not been widely 
utilised for biopharmaceutical purposes (Forbes and Ehrhardt 2005). 
 
1.2.1.2.Tracheo-bronchial epithelial cell lines  
 
In addition to significantly reduced costs, a major advantage of using immortalised 
airway epithelial cell models over primary lung airway epithelial cells is the ability 
to reduce the variability in cultures that arise from donor to donor differences. 
In contrast to gastrointestinal in vitro testing where Caco-2 cells have emerged as 
the gold standard, there is no such consensus to date on the preferred cell line(s) 
for modelling the bronchial epithelium in vitro. Several detailed protocols for culture, 
maintenance, growth and permeability assessment of tracheo-bronchial epithelial cell 
lines have been published in recent years (Forbes and Ehrhardt 2005; Sakagami 
2006), with the most commonly used systems being the Calu-3 and 16HBE14o- cell 
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lines. Additionally, the BEAS-2B cell line is frequently used for studies 
of metabolism and the interaction of cells with xenobiotics. A newly developed cell 
line, NuLi-1, has also recently been explored for similar purposes (Zabner, Karp 
et al. 2003).  
 
Calu-3 (American Type Culture Collection; ATCC HTB-55) is a human bronchial 
epithelial cell line derived from an adenocarcinoma of the lung (Fogh and Trempe 
1975). This cell line has been shown to exhibit serous cell properties and form 
confluent monolayers of mixed cell phenotypes, including ciliated and secretory 
(Shen, Finkbeiner et al. 1994), but the cilia of these cells are highly irregularly and 
seem to disappear with increasing passage number (unpublished observations CE & 
BF). Calu-3 cells have shown utility as a model to examine transport (Foster, Oster 
et al. 1998; Mathia(s), Timoszyk et al. 2002; Grainger, Greenwell et al. 2006) and 
metabolism in human bronchial epithelial cells for many therapeutic compounds 
(Florea, Cassara et al. 2003). Furthermore, they have been used in a number 
of particle-cell interaction studies (Fiegel, Ehrhardt et al. 2003; Cooney, 
Kazantseva et al. 2004; Amidi, Romeijn et al. 2006).  
 
Another continuous bronchial epithelial cell line, 16HBE14o-, was generated by 
transformation of normal bronchial epithelial cells obtained from a one-year-old 
male heart-lung transplant patient. Transformation was accomplished with SV40 
large T antigen using the replication defective pSVori- plasmid (Cozens, Yezzi et al. 
1994). 16HBE14o- cells can be obtained from Dieter C. Gruenert, Ph.D., at 
the California Pacific Medical Center (San Francisco, CA). Although this cell lines is 
a good lung epithelial model, it has been less widely used than Calu-3 most likely 
because it is not commercial available. 16HBE14o- cells have a non-serous, non-
ciliated phenotype and are generally rounder in shape and smaller in size than Calu-
3. When grown under liquid-covered culture (LCC) conditions, 16HBE14o- form 
confluent, polarised cell layers with functional tight junctions and several drug 
transport proteins are expressed (Ehrhardt, Kneuer et al. 2002; Ehrhardt, Kneuer 
et al. 2003). In contrast, air-interfaced culture (AIC) conditions lead to cell layers 
of less desirable phenotypic and morphological traits. Since most epithelial cells that 
are normally located at an air interface in vivo function optimally under AIC 
conditions for cultivation, the superior performance of the 16HBE14o- cell line 
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under LCC conditions is an exception for which the exact reasons or mechanism are 
currently unknown. Like Calu-3, the 16HBE14o- cell line has been utilised for drug 
absorption and particle-cell interaction studies (Forbes, Lim et al. 2002; Manford, 
Tronde et al. 2005). Figure 3 compares absorption rate constants across Calu-3 and 
16HBE14o- cell layers with in vivo rate constants determined for absorption from 
the rat lung after intra-tracheal delivery of various molecules (Ka).  
 
Figure 3: Apparent permeability coefficients (Papp)  observed in vitro across 
Calu-3 (●) (Mathia(s), Timoszyk et al. 2002) and 16HBE14o- (○) (Manford, Tronde 
et al. 2005) cell layers vs. in vivo rate constants determined for absorption from 
the rat lung after intra-tracheal delivery of various molecules (Ka) (Ehrhardt and Kim 
2008). 
 
 
The BEAS-2B cell line was derived from normal human epithelial cells that were 
immortalised using an adenovirus 12 and simian virus 40 hybrid (Reddel, Ke et al. 
1988). BEAS-2B is available from the ATCC (CRL-9609) and has been popular 
for use in studies of airway epithelial cell structure and function including 
phenotyping and mechanistic investigation of cytokine regulation (Atsuta, Sterbinsky 
et al. 1997). BEAS-2B cells have also been used to evaluate responses to challenges 
such as tobacco smoke (Sun, Wu et al. 1995), environmental particles (Veranth, 
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Kaser et al. 2007), and hyperoxia (Odoms, Shanley et al. 2004). Because it is 
challenging to generate TEER values higher than 100 ohm·cm2 using BEAS-2B cells 
(Noah, Yankaskas et al. 1995), this cell line is not frequently in drug permeability 
studies, but is more commonly used to investigate the expression and activity of drug 
metabolising enzymes (Proud, Subauste et al. 1994; Eaton, Walle et al. 1996).  
 
A relatively new cell line, NuLi-1, developed from primary airway epithelial cells 
infected with retroviruses expressing hTERT and HPV-16 E6/E7, has not to date 
been characterised for its use in biopharmaceutics (Zabner, Karp et al. 2003). When 
grown on collagen-coated, semi-permeable membranes (Millicell-PCF), NuLi-1 
TEER decreased over 30 passages from 685±31 to 389±21 ohm·cm2. The TEER 
of NuLi-1 over 30 passages is within reasonable range of that observed 
in the primary bronchial cultures (532±147 ohm·cm2). Thus, NuLi-1 cells can form 
an electrically tight
 
airway epithelial barrier that mimics the active and passive 
ion transport properties of primary human bronchial epithelial cells (Zabner, Karp 
et al. 2003).  
 
1.2.1.3. In vitro models of cystic fibrosis airway epithelium 
 
Cystic fibrosis (CF) is an autosomal recessive disease and is the most common lethal 
genetic disease in the world (O'Dea and Harrison 2002). There are approximately 
30,000 patients in the USA and Europe (Boucher 2004; Laube 2005). CF is caused 
by mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
located at chromosome 7 and is most commonly associated with defective chloride 
transport in airway epithelial cells. Lung pathology in CF includes abnormally low, 
and in extreme cases nil, chloride transport, increased mucus viscosity, reduced 
mucociliary clearance rates, recurrent infections, chronic inflammations and airway 
damage (Boucher 2004). Because of the significance of the disease, the most visible 
gene therapy schemes in development are inhalable regimens containing 
DNA complimentary to CFTR to treat CF by restoration of CFTR 
function in the airways of the lung. 
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In vitro models based on CF airway epithelium have been used widely in order 
to better understand CF pathophysiology, study alterations in airway permeability, 
and to assess the efficiency of gene vectors. Utilising approaches similar to those 
for cultivation of cells from healthy tissues, several protocols have been developed 
to culture airway epithelial cells harvested from CF patients (Gruenert, Basbaum 
et al. 1990). The development of immortalised cell lines with a CF phenotype has 
been significantly beneficial for investigators in the CF field by alleviating the major 
limitation inherent in primary cell culture models: the very limited availability 
of suitable CF tissues (Gruenert, Finkbeiner et al. 1995; Gruenert, Willems et al. 
2004). A number of these CF cell lines have been reported exhibit polarisation of cell 
layers with the necessary bioelectrical tightness to make them potentially useful 
for drug permeability studies. Examples of human immortalised CF airway epithelial 
cell lines are NCF3 (Scholte, Kansen et al. 1989), CFT1 (Olsen, Johnson et al. 1992), 
CFBE41o- (Ehrhardt, Collnot et al. 2006) and CuFi-3 and -4 (Zabner, Karp et al. 
2003). It should be noted that only the CFBE41o- and CuFi cell lines have been 
characterised and validated regarding their long-term stability as reliable in vitro 
models. 
 
1.2.2. In vitro models of the alveolar airspace 
1.2.2.1.Primary alveolar epithelial cell culture models  
 
Due to the paucity of appropriate alveolar epithelial cell (AEC) lines that form 
functional tight junctions, primary cultures of AEC are used for most in vitro studies 
of alveolar epithelial function (e.g., solute transport and metabolism). Primary 
mammalian AEC techniques involve isolation, purification, and culture of ATII cells 
from tissues obtained after lung resections or from isolated perfused lungs. These 
ATII cells, when plated on permeable supports or plastics under appropriate culture 
conditions, acquire type I cell-like phenotypes and morphologies (Danto, 
Shannon et al. 1995; Fuchs, Hollins et al. 2003; Demling, Ehrhardt et al. 2006). 
Mocular markers and lectins present in AT I and AT II epithelial cells are listed 
in Table 2: Molecular markers and lectins used for differentiation analysis between 
alveolar type I and type II epithelial cells 
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Table 2: Molecular markers and lectins used for differentiation analysis 
between alveolar type I and type II epithelial cells 
 
Alveolar type I cell Alveolar type II cell 
 
T1α* 
Aquaporin-4 (AQP-4) 
Aquaporin-5 (AQP-5) 
Receptor for advanced glycation end 
products (RAGE) 
Caveolin-1 
Fibroblast growth factor receptor-activating 
protein-1 (FGFR AP-1)* 
P2 purinergic receptor 7 (P2X7)* 
Interferon-induced protein* 
Bcl2-associated protein* 
 
Lycopersicon esculentum lectin 
Ricinus communis agglutinin 
Erythrina cristagalli lectin 
Bauhinia purpurea agglutinin  
Soybean lectin 
 
 
Surfactant protein (SP) -A, -B, -C and -D 
Aquaporin-3 
γ-aminobutyric acid receptor π-subunit 
(GABRP)* 
 
Maclura pomifera agglutinin 
Helix pomatia lectin 
Sambucus nigra agglutinin 
* not yet confirmed in human pneumocytes 
 
Although isolation of ATI pneumocytes from rat lungs has recently been reported 
with some success (Borok, Liebler et al. 2002; Johnson, Widdicombe et al. 2002; 
Chen, Chen et al. 2004), development of a confluent ATI cell monolayer with 
electrically tight characteristics has not been reported yet. It should be noted that 
unlike many other cells in primary culture, AEC generally exhibit a very limited 
proliferation profile and are therefore not suitable for passaging. Thus, a new 
preparation of cells has to be used for each data set which is tremendously costly. 
Furthermore, a necessary, reliable normalisation scheme for data observed from each 
set of cell preparations has not been developed. 
 
Due to the lack of availability of human lung tissues and ethical issues pertaining 
to use of human tissues, most lung permeability studies have been based 
on isolation and culture of cells from the lungs of animals including mouse (Corti, 
Brody et al. 1996), rat (Goodman and Crandall 1982), rabbit (Shen, Elbert et al. 
1999) and pig (Steimer, Franke et al. 2007). Since evidence for species differences 
between human and rodents might be more significant than once assumed (King and 
Agre 2001), confirmation using human pneumocyte cultures has been performed 
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for various aspects (Bingle, Bull et al. 1990; Ehrhardt, Kim et al. 2005; Wang, Edeen 
et al. 2007). 
 
1.2.2.2. Alveolar epithelial cell lines 
 
While a number of immortalised cell lines emanating from different cell types 
of the airway (i.e., tracheo-bronchial) epithelium of lungs from various 
mammalian species are available (see above), reliable and continuously growing cell 
lines that possess alveolar epithelial cell morphology and phenotype have not been 
reported to date. Most studies have relied on the use of cell lines of alveolar 
epithelial origin for drug absorption studies with observations that are hard or 
meaningless to extend to humans. 
 
The most frequently used alveolar epithelial model is the A549 cell line 
(American Type Culture Collection, ATCC CL-185); a continuously growing cell 
line derived from a human pulmonary adenocarcinoma that has some morphologic 
and biochemical features of the human pulmonary alveolar type II cell in situ 
(Lieber, Todaro et al. 1976). A549 cells contain multilamellar cytoplasmic 
inclusion bodies, like those typically found in human lung ATII cells, although these 
hallmarks disappear as culture time increases. At early and late passage levels, 
the cells synthesise lecithin with a high percentage of disaturated fatty acids utilising 
the cytidine diphosphocholine pathway (Lieber, Todaro et al. 1976). The cell line has 
been utilised for many biopharmaceutical studies despite the fact that A549 cells lack 
the ability to form tight monolayers of polarised cells due to their inability to form 
functional tight junctions (Foster, Oster et al. 1998; Elbert, Schäfer et al. 1999; Kim, 
Borok et al. 2001; Forbes and Ehrhardt 2005).  
 
Figure 4 highlights the differences in morphology between primary human alveolar 
epithelial cells (hAEpC) that started as ATII cells and differentiated into ATI-like 
morphology at 8 days in primary culture (Panel A) and A549 cells on day 5 
in culture (Panel B) by light microscopy. In addition, Figures 4C and 4D show 
results of immunofluorescence microscopy using an antibody against occludin 
(a tight junctional protein) for the hAEpC monolayer and A549 cells, respectively. 
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Figure 4: Morphological diferences between human alveolar epithelial cells 
in primary culture at day 8 (A and C) and the A549 cell line at 5 days (B and D). 
Cells are visualised by light microscopy (A and B) and immunofluorescence 
microscopy (C and D), (Ehrhardt and Kim 2008). 
 
 
 
 
Despite their obvious unsuitability due to a lack of good transepithelial electrical 
resistance, some investigators still employed A549 cell layers in drug 
absorption studies (Kobayashi, Kondo et al. 1995). The absorption data reported by 
these groups were not able to clearly show differences in transport rates between 
proteins and peptides of various sizes where the published permeability values were 
2-4 orders of magnitude higher than those obtained in tight monolayer systems (e.g., 
hAEpC monolayers) using identical compounds (Forbes, Lim et al. 2002). Moreover, 
the reported A549 TEER of ~600 ohm·cm2 by one group (Kobayashi, Kondo et al. 
1995) may be in gross error. Their data indicate that large hydrophilic molecules are 
translocated across A549 cell layers at rates approaching near-free diffusion limits. 
In other words, such large fluxes probably took place via large gaps between A549 
cells, contradictory to the very large TEER they reported. It should be noted that 
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the TEER of A549 cells is usually in the range of 20 - 60 ohm·cm2. These lower, 
measured TEER values are consistent with the knowledge that no functional tight 
junctions are present in A549 cell layers (Foster, Oster et al. 1998; Elbert, Schäfer 
et al. 1999). Notwithstanding, A549 cells might still be a useful model in other areas 
of biopharmaceutical research, including metabolism or cytotoxicity studies 
for various substances (Foster, Oster et al. 1998; Forbes, Wilson et al. 1999; 
Anabousi, Bakowsky et al. 2006).  
 
Other cell lines of an alveolar epithelial origin used in published studies include 
H441 (human), MLE-12 and 15 (mouse), and L-2 and R3/1 (rat). Of these, the NCI-
H441 cell line (ATCC HTB-174), originating from a human lung adenocarcinoma, 
has been described as having characteristics of both ATII (Duncan, Whitsett et al. 
1997; Rehan, Torday et al. 2002) and bronchiolar (i.e., Clara) epithelial (Zhang, 
Whitsett et al. 1997; Newton, Rao et al. 2006). Studies can thus be designed 
to characterise metabolism and transport properties of these two particular cell types 
in a single culture. There is emerging evidence that H441 cells are capable 
of forming polarised monolayers that exhibit significant transepithelial electrical 
resistance (Shlyonsky, Goolaerts et al. 2005; Woollhead and Baines 2006), but 
the cell line has not been used for drug absorption experiments to date. 
 
Wikenheiser and co-workers generated a series of continuous alveolar epithelial cell 
lines [MLE-7, -12, and -15] from transgenic mice harbouring the SV40 large T 
antigen under the control of the human SP-C promoter region. These MLE cell lines 
maintained morphological and functional characteristics of distal respiratory 
epithelial cells normally lost after isolation and primary culture (Wikenheiser, 
Vorbroker et al. 1993), which are consistent with those seen in non-ciliated 
bronchiolar and ATII epithelial cells. However, morphological and functional 
characteristics associated with an individual cell type do not appear to always co-
exist in a clonal cell line. 
 
The L-2 cell line (ATCC HTB-149) is derived from cells isolated from the adult rat 
lung using clonal culture techniques. These cells appear to retain differentiated 
functions that are present in ATII cells of intact rat lungs. L-2 cells are diploid, 
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epithelial cells. They contain osmiophilic lamellar bodies in their cytoplasm and 
synthesise lecithin by the same de novo pathways as in a whole lung (Douglas and 
Kaighn 1974). It is not known if L-2 cells are capable of forming confluent and 
electrically tight monolayers. L2 cells have not been systematically investigated 
for suitability as a model for absorption studies. 
 
In 2004, the rat cell line R3/1 was established from cells obtained from broncho-
alveolar tissues of foetal Han-Wistar rats at 20 days of gestation. This cell line 
displays a phenotype with several characteristic features of ATI cells. R3/1 cells 
were analysed to express mRNA and protein markers related to the ATI cell type 
(i.e., T1α, ICAM-1, connexin-43, caveolins-1 and -2 and receptor for advanced 
glycation end products (RAGE)). Moreover, lectins Bauhinia purpure agglutinin 
(BPA) and Soybean lectin (SBA) which are characteristic for ATI in normal rat lung 
were bound to R3/1 cells (Koslowski, Barth et al. 2004; Reynolds, Kasteler et al. 
2008). To assess potential ATII cell properties, presence of surfactant proteins SP-A, 
SP-B, SP-C and SP-D was investigated and compared with normal rat lung tissue. 
AT II cells in lung tissue showed strong expression of all SPs; R3/1 cells displayed 
moderate staining for SP-A and SP-B, while SP-C and SP-D were not found. R3/1 
cell line was also tested for expression of mesenchymal marker proteins (Barth, 
Gentsh et al. 2005). R3/1 cells exhibited a mixed phenotype of epithelial (aquporin-5 
and cytokeratin-8) and myofibroblast-like (vimentin, α-smooth muscle actin and 
caveolin-3) features suggesting that this cell line was established from cells at 
certain stage during epithelial-mesenchymal transition. The AT I-like cell line R3/1 
seemed to be a promising in vitro model for the study of lung biology. 
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2.  OBJECTIVES OF THE STUDY 
 
The aim of the study was to characterise the rat alveolar R3/1 cell line regarding its 
property to form tight cell monolayers as necessary for in vitro models used for drug 
absorption studies. Additionally, the presence of peptides degrading enzymes was 
to be analysed in R3/1 cells to describe the cell line as a possible model 
for protein stability studies.  
 
In order to characterise the cell line as in vitro model for drug disposition studies, 
R3/1 cells were cultured on filter inserts under various conditions. The transpithelial 
electrical resistance was measured as a parameter for integrity of cell layers. 
Molecular biological techniques (RT-PCR, Western blot, immunofluorescence 
microscopy) were employed to investigate expression of tight junction proteins 
(occludin, E-cadherin and ZO-1 and ZO-2 proteins) and proteolytic enzymes 
on mRNA and protein levels. 
 
2.1.Theoretical background 
 
2.1.1. Tight junctions 
 
Two adjacent epithelial cells are tightly connected together to seal paracellular 
pathway and separate apical and basolateral part of cells in order to allow active 
transport across cell layers. These cell connections can be divided into four 
subcategories of junctions (Figure 5) tight junctions (TJs), adherens junctions (AJs), 
gap junctions (GJs) and desmosomes. TJ, AJ and GJ which are located at the most 
appical region of cells creates the junctional complex (Tsukita, Furuse et al. 2001; 
Balkovetz 2006).  
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Figure 5: Junctional complex and tight junction. (Tsukita, Furuse et al. 2001): 
a schematic drawing of epithelial cells (intestine) 
b electron micrograph of the junctional complex. 
 
 
 
The junctional complexes consist of number of transmembrane and cytosolic 
proteins; function of many of them is not completely investigated up to date. 
Architecture of proteins involved in TJ is shown on Figure 6. Some proteins are 
specific to one type of junction only, others can be found in several types. In TJs, 
contact between adjacent cells is provided with transmembrane domains 
of occludin and of claudin family. Number of cytosolic proteins (zonulae occludens 
proteins 1-3 (ZO-1, -2 and -3, etc), fodrin, etc.) is associated with occludin and 
claudins (Mitic and Anderson 1998; Fanning, Mitic et al. 1999) and thus a linkage 
of TJ proteins with cytoskeleton is provided. Junctional adhesion molecules (JAMs; 
JAM 1-3) are a family of immunoglobuline superfamily proteins colocalized with 
occludin and claudins at TJ level of epithelial and endothelial cells. JAMs have been 
shown to bind to TJ-associated cytoplasmic proteins although their role in TJs has 
still not been identified, JAM protein complex regulates paracellulr permeability 
(Mandell and Parkos 2005; Vandenbroucke, Mehta et al. 2008).  
 
Adherens junction (AJ) is the most frequent junction in the endothelial barrier (TJs 
are the most common in the epithelium). The transmembrane part of AJs consists 
mainly of E-cadherin and nectin transmembrane proteins connected to actin via 
cytosolic α-catenin and afadin (Niessen and Gottardi 2008). 
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Figure 6: Organisation of integral membrane proteins in TJs (Fanning, Mitic 
et al. 1999) 
 
 
GJs interconnect the cytoplasm of adjacent cells through structures called connexons. 
Each connexon (Cx) comprises 6 polypeptide subunits (connexins) arranged radially 
to form a pore (Koval 2002; Yeager and Harris 2007; Alldredge 2008). These pores 
enable direct diffusion of small molecules and ions from one cell to the neighbour 
one (Koval 2002). 
 
Cell-cell junctions desmosomes maintain the structural integrity of tissues. 
Desmosomes connect two adjacent cells in lateral edges. The transmembrane part 
of desmosome molecular complex is formed by desmogleins and desmocollins; 
proteins of cadherin family (Stokes 2007; Garrod and Chidgey 2008). 
 
2.1.2. Proteolytic enzymes 
 
The availability of peptides is limited by activity of proteolytic enzymes (Kobayashi, 
Kondo et al. 1996; Yamamoto, Fujita et al. 1996; Forbes, Wilson et al. 1999). 
Peptidases are enzymes responsible for cleavage and thus possible 
inactivation of small protein molecules. They are present on the surface of tissues 
in the whole body and take part in various processes. Peptidases are classified 
according to the site of their effect in their substrates, endopeptidases cleave 
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molecule of the substrate in the middle of the peptide, exopeptidases at the contrary 
romove aminoacids either from one of the ends of peptide chains. According 
to the site of action, exopeptidases are divided into group of aminopeptidases 
cleaving aminoacids (AAs) from N-terminus and carboxypeptidases removing AAs 
from C-terminus of peptide (Van Der Velden and Hulsmann 1999). From a wide 
range of peptidases, the interest of this study (Table 3) focused mainly on peptidases 
whose presence in the lung has been shown already although usually without 
information specifying localization within the lung regions.  
 
Table 3: Peptidases in the lung 
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Summary of the literal sources of Table 3: 
Literature  
A Van Der Velden and Hulsmann 1999 
B Baraniuk, Ohkubo et al. 1995 
C Dragovic, Igic et al. 1993 
D Nagae, Abe et al. 1993 
E Van Der Velden, Wierenga-Wolf et al. 1998 
F Forbes, Wilson et al. 1999 
G Rahman, Bel et al. 1998 
H Joyce-Brady, Takahashi et al. 1994 
I Foulon, Cadel et al. 1999 
J Cadel, Gouzy-Darmon et al. 2004 
K Albiston, Ye et al. 2004 
L Chu and Orlowski 1985 
M Lojda and Gossrau 1980 
N Prechel, Orawski et al. 1995 
O Wang, Toledo-Velasquez et al. 1993 
 
 
2.2. Principles of methods 
 
2.2.2. TEER 
 
The transepithelial electrical resistance (TEER) is determined by formation of tight 
junctions. According to Ohm´s law, TEE = (PD/Isc) x A; where PD is potential 
difference, Isc short-circuit current and A is permeation area. Epithelial cells have 
asymmetric distribution of ion channels on the apical and basolateral membranes, PD 
is equal to the difference between the voltage of the apical and basolateral 
membranes. Isc is defined as the charge flow per time when the cell monolayer is 
short-circuited, i.e. PD is maintained zero value. A corresponds with the surface 
area of filter. Epithelial Volt Ohm Meter (EVOM) (Figure 7) measures resistance 
across the membrane using a pair of chopstick electrodes placed in contact with 
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media on apical as well as basolateral side of membrane. The advantage of this 
method is that the checking of membranes is non-destructive. 
 
Figure 7: Example of epithelial voltohmmeter  
(http://www.pharmaceutical-int.com/images/companies/1529/wpi17.jpg) 
 
 
 
 
2.2.2. RT-PCR 
 
Polymerase chain reaction (PCR) allows synthesise copies of sequence of particular 
DNA. A typical cycle of PCR involves 3 steps: denaturation, annealing and 
elongation step. After initialisation of PCR, i.e. heating reaction mixture for couple 
of minutes at temperature close to 95°C; denaturation step takes place. During 
denaturation, strands of DNA and primers are melted by disruption of hydrogen 
bonds in their structures. After that, primers can align to DNA strand (for this, 
optimal conditions like temperature or concentration of Mg
2+ 
ions for each primer 
pairs are required). For the last step, primers elongation, optimal temperature is 
dependent on polymerase enzyme used. Polymerase synthesises new DNA strand 
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from dNTPs. When the replication of the segment between the two primers (one 
cycle) is complete, the two new duplexes are heated and denaturated to single strand 
templates. With increasing number of repetition of cycles of synthesis and 
denaturation, usually 25-40 times, sequences of DNA of defined length are 
exponentially amplified and the product of PCR is run on gel electrophoresis 
to visualise product and its size (Figure 8). 
 
 
Figure 8: Schematic drawing of PCR method 
(http://www.obgynacademy.com/basicsciences/fetology/genetics/images/pcr.png) 
 
 
 
 
2.2.3. IFM 
 
Cells to be examinated with immunofluorescent microscopy (IFM) are grown 
on solid supports, fixed and permeabilised to allow antibodies to access 
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to intracellularly located antigen. Fixation can be done either with organic solvents 
(acetone, methanol) with the mechanism of removing lipids and 
dehydratation of cells or with cross linking agent (paraformaldehyde) creating 
intermolecular bridges usually through free amino-acids groups. Fixed and 
permeabilised specimens are then incubated with antibody. Unbound antibody is 
washed out and the bound antibody is either detected directly (if the primary 
antibody is labelled) or indirectly (using a fluorochrome-labelled secondary 
antibody) (Figure 9). Stained preparations are evaluated using a fluorescent or 
confocal laser scanning microscope. 
 
Figure 9: Direct and indirect immunofluorescence 
(http://uk.geocities.com/mgormerod@btinternet.com/Figure4-1.jpg) 
 
 
2.2.4.  Immunblotting 
 
Western blot (WB) is an immunoblot technique by which proteins can be detected 
in tissue or other samples. At the first stage, samples precede gel electrophoresis, 
in most cases SDS-polyacrylamide gel electrophoresis (SDS-PAGE); the mobility 
of proteins through gel matrix is dependent on their size and 
concentration of acrylamide. Before electrophoresis itself, samples are treated with 
solution containing β-mercaptoethanol and SDS (sodium dodecyl suplhate). β-
mercaptoethanol cleaves disulfide bonds while SDS (anionic detergent) denaturates 
proteins and gives them negative charges. This negative charge dominates over 
intrinsic charge of protein, so during electrophoresis migration of proteins depends 
only on their sizes (Figure 10). Proteins resolved by electrophoresis are transferred 
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onto cellulose or polyvinylidene fluoride (PVDF) membranes. Proteins are 
negatively charged (SDS coating effect) and move from negative side (gel) towards 
positive electrode side, represented by membrane. Protein molecules are identified 
by probing the blot with antibody to specific protein (Figure 11a). 
 
Figure 10: Gel electrophoresis 
(http://www.life.umd.edu/classroom/bsci423/song/F03-41.jpg) 
 
 
 
 
 
 
Membranes are first incubated with blocking agent that blocks non-specific protein 
binding sites and then blotted with primary antibody specific for the protein 
of interest. Unbound primary antibody is washed away and membranes are incubated 
with secondary antibody which is specific for primary antibody and conjugated with 
horseradish peroxidase (HRP) (Chyba! Chybný odkaz na záložku.b). 
HRP substrate is added after washing and HRP catalyses reaction in which colourless 
substrate is transformed into coloured product which visualise the protein band 
(Figure 11c).  
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Figure 11: Protein transfer, detection and development 
(http://www.life.umd.edu/classroom/bsci423/song/Lab12.html) 
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3. MATERIALS AND METHODS 
3.1.  Cell culture 
3.1.1.  R3/1 cell line 
 
R3/1 cells of passage numbers 40-59 were grown in 75 ml flasks in an 1:1 mixture 
of Dulbecco‘s modified Eagle‘s medium (DMEM) and Ham´s F-12 medium (Sigma, 
Dublin, Ireland) at 37°C in 5% CO2 atmosphere (Figure 12).  
 
Figure 12:  Culture of R3/1 cells 
 
 
 
The DMEM/Ham‘s F-12 was supplemented with 10% (v/v) foetal bovine serum 
(FBS), 1% (v/v) non-essential amino acids, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 10 mM HEPES. Moreover, RPMI 1640 supplemented with 10% 
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin was used as an alternative 
medium.Cells were fed with 14 ml of fresh media every 2 days. Cells were split 
when confluent by trypsin EDTA solution, before trypsination cells in flask were 
washed twice with 10 ml of PBS. Washed cell layers were topped with 3 ml 
of trypsin/EDTA solution and the flask was placed into incubator (37°C, 5% CO2) 
for 3 minutes to allow cell detachment. After that, trypsin/EDTA solution was 
inactivated with 7 ml of media and cell suspension was homogenised by pipetting 
several times up and down. Cells were counted manually using a Neubauer-type 
hematotocytometer, a calibrated counting chamber with identically duplicate 
counting areas. A cover glass placed over the chamber provides a depth of 0.1 mm. 
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Each chamber area is divided into squares of equal sizes, 50 µm on each side. 50 µl 
of homogenised cell suspension was pipetted into sterile Eppedorf tube and mixed 
with the same volume of tryptan blue solution (Sigma). Tryptan blue staining method 
is based on the principle that polar dye can hardly cross viable cell membranes but 
damaged or leaky membranes allow to the dye to intracellular proteins. Under 
the detection under a light microscope, tryptan blue gives blue colour to the dead 
cells while living cells stay transparent. Non-stained cells were counted in both parts 
of chamber and if this numbers did not differ more than 10%, average number from 
these two countings was used for further calculation. According to parameters 
of hematocytometer, cells concentration per 1 ml was obtained when multiplying 
the number of cells counted in chamber by 20.000.  
 
To study the influence of media composition on R3/1 cell monolayer integrity, cells 
were seeded on Transwell Clear polycarbonate permeable filter inserts (Fisher 
Scientific, Dublin, Ireland) at densities of 0.5 - 8×105 cells/cm2 and cultured under 
liquid-covered culture (LCC) or air interfaced culture (AIC) conditions. The effect 
of dexamethasone (DEX, 0.1 μM) and FBS (0-20%) in the culture medium 
on the cell function was assessed. 
 
3.1.2.  Primary alveolar epithelial cells 
 
Specific pathogen-free adult Sprague-Dawley male rats weighing 120-150 g were 
euthanized with sodium pentobarbital (2.5 mg/kg, i.p.). Rat lungs were perfused 
in situ with 0.9% NaCl solution and alveolar type II (AT II) cells were isolated from 
the lungs following elastase digestion (Kim, Cheek et al. 1991). The crude cell 
mixture was filtered sequentially through 100, 40, and 10 µm meshes, followed by 
plating onto IgG-coated bacteriological plates. After 1 h incubation, type II cells 
were collected and centrifuged at 150 g for 10 min for further enrichment. Purified 
rat type II pneumocytes were resuspended and either used directly or seeded 
onto Transwell
® 
filter inserts at 1.2 × 106 cells/cm2. Culture medium consisted 
of DMEM/Ham‘s F-12 1:1 supplemented with 10% (v/v) newborn bovine serum, 
100 U/ml penicillin and 100 μg/ml streptomycin. Cells were fed on day 3 and every 
other day thereafter. These monolayers transdifferentiated into cells bearing type I 
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cell-like morphology and phenotype (Borok, Hami et al. 1995). Total RNA was 
isolated from freshly isolated ATII cells or on day 8 of culture utilising type I cell-
like monolayers. 
 
3.2.  TEER 
 
TEER was measured as a parameter of integrity cell monolayer. Cells were seeded 
on Transwell
®
 Clear permeable filter inserts at densities 2 – 8 x 105 cells/ cm2 and 
cultured under LCC or AIC conditions. Cells were fed every second day with fresh 
media as follows: LCC grown cells were fed with 1,5 ml of media into basolateral 
part of filter and 0.5 ml of media into the apical compartment. Media for AIC cells 
were added into basolateral compartment only, in this case 650 µl was used for each 
filter. Cells were grown in three different culture media (RPMI 1640 supplemented 
with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin; DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml and streptomycin; 
and DMEM/F-12 Ham 1:1, complemented as above. Furthermore, 0.1 μM 
dexamethasone was added to the media. TEER was measured daily using a Millicell-
ERS epithelial voltohmmetre (Millipore, Carrigtwohill, Ireland) fitted with chopstick 
electrodes. Obtained values were corrected for background resistance contributed by 
filter and medium. TEER of Transwell filters with LCC culture was measured 
directly, cells cultured on filters under AIC had to be filled with media up 
to the volume of LCC conditions, i.e. up to 0.5 ml in apical and 1.5 ml in basolateral 
compartmen, and the TEER measurement itself was carried out at least 15 minutes 
after volumes were adjusted. 
 
3.3.  RT-PCR 
 
To assess the transcription of tight junction proteins as well as catabolic enzymes 
in R3/1 cells, the total mRNA was isolated using an RNeasy Mini kit (Quiagen, 
Crawley, UK). R3/1 cells were plated in 6-well cell culture plates at density 
20.000 cells/cm
2
, fed every second day with 3 ml of fresh media and harvested at day 
6 after seeding. Cells were lysed directly in 6-well plates with 350 µl of RLT buffer 
(supplemented with 10 µl of β-mercaptoethanol per 1 ml of RLT buffer), detached 
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with cell scraper and the lysate was homogenized by passing 5 times through needle 
fitted to a RNase free needle. The homogenized lysate was mixed with the same 
volume of 70 % ethanol and transferred on RNeasy spin column placed in 2 ml 
microcentrifuge tube and centrifuged for 15 s at 10.000 rpm. The flow-through was 
discarded and centrifugation was repeated with RW1 buffer followed by two 
centrifugations with RPE buffer. As a last step, 30 µl of RNase free water was added 
to the columns to elute mRNA. Messenger RNA was quantified by UV 
absorption at 260 nm using a spectrophotometer NanoDrop ND 1000, (NanoDrop 
Technologies, Wilmington, DE). 1 µl of each sample was pipetted onto the TrayCell 
– Fibre-Optical Ultra-Micro Measuring Cell (Hellma, Essex, UK), cap was fitted 
on the cell prior the measurement (Figure 13). The cap of the cell creates defined 
optical light path and due to integrated beam deflection and the use of fibre-optic 
cables, it was possible to measure the sample directly on the surface of the optical 
window. The measurement of mRNA concentration of particular sample was 
repeated 3 times with the same ‗drop‘ of sample, the cap prevented drying out 
of the samples or sample enrichment due to evaporation of the solvent. 
 
 
Figure 13: Hellma TrayCell (www.traycell.com/en/img/traycell_1_2.png) 
 
 
 
 
 
The purity of RNA was estimated by comparison absorption at 260 nm and 280 nm 
(the A260/A280 ratio), moreover quality of all mRNA samples were checked on 1 % 
agarose gel electrophoresis containing ethidium bromide. Samples were diluted 
with RNase free water to equal concentration (100 or 200 µg/ml) and potential 
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contaminating DNA was removed with Turbo DNA-free
TM
 (Ambion, Austin, TX). 
For 50 µl of reaction, 5 µl of TURBO DNase Buffer and 1 µl of TURBO DNase 
(2U/µl) were added to the RNA sample and this mixture was incubated 
for 30 min at 37°C using a Primus 96 Advanced Gradient termocycler (Peqlab, 
Erlangen, Germany). 5 µl of DNase Inactivation Reagent was put into the same tube 
and mixed occasionally at the room temperature. Tubes were then spun down and 
supernatant transferred into new tube and reverse transcription (RT) step followed 
immediately.  
 
20 µl of RT mix contained 6.5 µl of water, 4 µl of 5x first strand buffer 
supplemented with DTT (0.1M), 2 µl of dNTP Mix (10 mM each), 0.25 µl of random 
hexamers (50ng/ml), 5 µl of RNA, 0.5 µl of RNasin (40U/ µl) and 1 µl of MMLV-
RT (200U/µl) (BioscriptTM, Bioline, London, UK). Negative controls (i.e. MMLV-
RT was replaced with water) were run to eliminate samples with 
DNA contamination. RT-PCR amplification was performed using oligo primers 
(Eurofins MWG Operon, Ebersberg, Germany) as listed in Table 4.  
 
Table 4: Primer sequences 
 
Primer Sequence 
Product 
size 
Optimal 
temperatur
e 
β-actin 
forward GTCGTACCACTGGCATTGTG 
181 59°C 
reverse CTCTCAGCTGTGGTGGTGAA 
E-cadherin 
forward CCTAGCTGGAATCCTGTCCA 
164 62°C 
reverse CACCAACACACCCAGCATAG 
Occludin 
forward TCTCAGCCGGCATACTCTTT 
162 62°C 
reverse ATAGGCTCTGTCCCAAGCAA 
ZO-1 
forward CACCACAGACATCCAACCAG 
230 59°C 
reverse CACCAACCACTCTCCCTTGT 
ZO-2 
forward GGCCTGGACCATGAAGACTA 
232 59°C 
reverse GTTCATAGCGGGTCTCTGGA 
NEP 24.11 
forward CATTGCCGCAAGAACTCATA 
171 59°C 
reverse TGTGAATTTCCCCCAAGAAG 
EP 24.15 
forward GGTCCTGCACACACAGACAG 
198 59°C 
reverse TTGAAGCGTGTGTGGAACAT 
DPP IV 
forward GAGGCAGCTTGGAACATAGC 
225 59°C 
reverse TGCTAAATGACCAGGCAACA 
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CPM 
forward GATTCGAAGCCGTCAAGAAG 
185 58.4°C 
reverse ATGGAGATTCGCAGAGAGGA 
APM 
forward TTGTCAGACTGCCAGACACC 
199 59°C 
reverse TGTGCCCTGTTGATTCTTTG 
ACE 
forward AGTGGGTGCTGCTCTTCCTA 
188 59°C 
reverse ATGGGACACTCCTCTGTTGG 
GGT 
forward AAGACTCGGCACCACCATAC 
179 59.8°C 
reverse GTCCCACTCTCGTCTCTTGG 
APP 
forward TCCTCTCCCCAACTGTGAAC 
242 56.2°C 
reverse TCAGAGTCTGCCCACACAAG 
APA 
forward AAACCAGGATCACCAAGCTG 
156 62°C 
reverse TGGTCAGCCGATAGACACTG 
APB 
forward CTTCGAGATCCTGCACCTG 
247 56.2°C 
reverse GAAGGGCTGTGTGTGGAAAG 
 
 
Primer pairs were designed and picked from Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and aligned in BLAST 
database (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) to confirm their unique 
presence within target species. Each PCR reaction contained 40 ng of cDNA, 
1.5 mM MgCl2, 0.2 mM of each dNTPs, 1.25 μl Taq buffer, 0.1 μl Biotaq
TM
 
DNA polymerase (Bioline) (5U/ μl), 10pmol of each  forward and reverse primer and 
DEPC treated water up to of final volume 12.5 μl. To facilitate strand 
separation in cases PCR amplification did not produce acceptable results, dimethyl 
sulfoxide (DMSO) in final concentration 1-5% was added to the reaction mixture. 
PCR program started with 5 min at 95°C, followed by 35 amplification cycles 
(denaturation at 94°C for 30 s, annealing at optimal temperature for concrete primer 
pair for 45 s and extension at 72°C for 45 s). After the last cycle finished, 
the reaction was terminated with final extension step for 10 min. at 72°C. 
At the beginning, each of designed primer pairs was optimized over the temperature 
gradient (54 - 62°C) using either rat genomic DNA or rat cDNA obtained from 
transcription of mRNA isolated from rat lung or duodenal tissue. Negative and 
positive controls were run in the same procedure; HyperLadder IV (Bioline) was 
used as a DNA size marker. The PCR products were mixed with 3 μl of 5x loading 
buffer (Bioline) and separated by 2% agarose gel electrophoresis containing ethidium 
bromide (0.2 μg/ml gel) in 0.5 x TBE buffer. 
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5x TBE buffer (stock solution) 
 
Tris Base 54.0 g 
Boric acid 27.5 g 
Na2EDTA.2H2O 3.7 g 
H2O dd Up to 1000 g 
Bands were visualised under UV light using a ChemiDoc
TM
 Bio-Rad system.  
 
3.4.  Immunofluorescence Microscopy  
 
The mouse monoclonal anti-occludin antibody (Zymed, San Francisco, CA) was 
diluted 1:100 in PBS containing 1% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich, Dublin). Mouse IgG1 (clone MOPC-21, Sigma) was used as an isotypic 
control. Transwell-grown R3/1 cells were stained on day 6 after cell plating. Filters 
were washed twice with PBS (apical and basolateral side). Cells were fixed 
for 10 min with 2% (w/v) paraformaldehyde (PFA). To prepare PFA solution, 1 g 
of PFA was added into 50 ml of PBS. Solution was warmed up in water bath 
with temperature not exceeding 70 °C in a fume hood. Few drops of 1M NaOH 
solution were added to facilitate the solubilisation, solution was cooled down in room 
temperature and pH was adjusted to 7.4. PFA is then blocked for 10 min in 50 
mM NH4Cl, followed by permeabilisation for 8 min with 0.1% (w/v) Triton X-100. 
After a 60 min incubation with 100 μl of the diluted primary antibody, the cell layers 
were washed three times with PBS before incubation with 100 μl of a 1:100 
dilution of an Alexa Fluor 488-labelled goat anti-mouse F(ab′)2 fragment 
(BioSciences, Dun Laoghaire, Ireland) in PBS containing 1% (w/v) BSA. Propidium 
iodide (PI; 1 μg/ml) was then added to counterstain cell nuclei. After 
30 min incubation, the specimens were washed three times with PBS. Filters were 
cut out and embedded in FluorSave anti-fade medium (Calbiochem, San Diego, CA). 
Specimens were stored in dark place for at least one hour prior microscopy analysis. 
Images were obtained on a fluorescence microscope (Zeiss Axiovert 200, Gőttingen, 
Germany). 
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3.5. Western blotting 
 
R3/1 cells were treated with FBS free medium for 24 h. Medium was collected and 
used for analysis of soluble enzymes. For analysis of membrane bound enzymes, 
cells were washed twice with cold PBS and lysed with Cell Extraction Buffer 
(BioSciences) supplemented with proteases inhibitors leupeptin (10 μg/10ml 
of buffer) and aprotinin (60 μg/10 ml of buffer) (Sigma). Cells were detached with 
cell scraper; detachment was monitored by light microscopy. Cells were transferred 
into Eppendorf tube and membranes were disrupted with ultrasound needle 
(Microson ultrasonic cell XL-2000, Misonix Incorporated, Farmingdale, NY) – 
2 bursts of 10 s each separated by 30 s cooling on ice. Samples from rat kidney and 
lung tissues passed through similar procedure with 4 bursts with ultrasound needle 
in total. After centrifugation (20 min at 10.000 rpm, 4°C), supernatant was collected 
into new Eppendorf tube and kept on ice. Concentration of proteins in all samples 
was carried out in a protein assay (Bradford 1976) assay using BSA as a standard 
(Bio-Rad Protein Assay Kit, Bio-Rad, Hercules, CA). Samples were diluted 
to the same concentration, western blot loading buffer (containing SDS and β-
mercaptoethanol) was added (18 μl of sample + 6 μl of loading buffer), and samples 
were boiled for 3 min and spin down. In meantime, gels containing polyacrylamide 
and methylenbisacrylamide (separating/resolving gels) were prepared. 
Concentration of polyacrylamide in resolving gel differed from 5 to 15 % according 
to the size of target protein. 
 
Separating gel (8% polyacrylamide): 
30% acrylamide/0.8% bisacrylamide solution 4000 μl 
4x Tris.Cl/SDS; pH 8.8 3750 μl 
H2O dd 7250 μl 
10% ammonium persulfate (APS)(= 0.1 g APS + 960 μl H2Odd) 50 μl 
N,N,N',N'-tetramethylethylenediamine (TEMED) 10 μl 
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This amount was enough for 4 gels of mini blot size (8.6 x 6.8 cm). Mixture was 
poured between two glass crystals and topped with water to prevent 
oxidation and allow polymerisation to start. After polymerisation, sharp border 
between gel and water occurred and water from the top of polymerised gel was 
removed. Stacking gel was poured instead of water, comb creating pockets was 
inserted and gel was left to polymerise.  
 
Stacking gel (for 4 gels): 
30% acrylamide/0.8% bisacrylamide solution 1300 μl 
4x Tris.Cl/SDS, pH 6.8 2500 μl 
H2O dd 6000 μl 
10% APS 50 μl 
TEMED 10 μl 
 
When the gel became solid, comb was carefully removed, two gels were assembled 
together and gap between them was filled with 1x tank buffer.  
 
10x Tank buffer: 
Tris base 30.2 g 
Glycine 144 g 
SDS 10 g 
H2O dd 700 ml 
Adjust to pH 8.3  
H2O dd                                             up to 1000 ml 
 
20 µl of the boiled sample mixture (containing WB loading buffer) was loaded 
into pocket, 10 μl of Precision plus Protein standard (Bio-Rad) was used as a ladder. 
Gel electrophoresis was run in 1x Tank buffer (150 V, time of electrophoresis run 
was dependent on percentage of acrylamide in gels and size of target protein). When 
electrophoresis finished, stacking part of the gel was cut off and the gel was washed 
while rocking for half an hour in Towbing transfer buffer (TTB). 
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TTB: 
Tris base 12.12 g 
Glycine 57.6 g 
SDS 2 g 
Methanol 800 ml 
H2O dd Up to 4000 ml 
 
PVDF membranes (Immun-Blot PVDF Membrane, Bio-Rad) were activated by 
submersion for 30 s in methanol, activated membranes as well as Blot papers 
(Extra thick blot paper Mini blot size, Bio-Rad) were left in TTB for at least 5‘ prior 
transfer. Each WB sandwich consisted of blot paper, PVDF membrane, 
polyacrylamide gel and another blot paper (Figure 14). 
 
Figure 14: Semi-dry WB transfer 
 
 
 
Proteins were transferred from gels onto membrane using TRANS-BLOT® Semi-
Dry Electrophoretic Transfer Cell (Bio-Rad), at 25 V for 30 min. When transfer 
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finished, membranes were rocked overnight at 4°C in blocking buffer (5% of dry fat 
free milk in washing buffer). 
 
Washing buffer: 
20 % TWEEN 20 5 ml 
2M Tris-HCl 5 ml 
NaCl 5.844 g 
H2O dd Up to 1000 ml 
 
Next day, membranes were warmed up to room temperature and washed for 2 h 
in primary antibodies solution in blocking buffer. For detailed dilution of primary 
antibodies see Table 5. 
 
Table 5: Primary antibodies working concentrations 
 
Primary Antibody Working dilution 
Goat polyclonal anti-aminopeptidase A 1:100 – 1:200 
Mouse monoclonal anti-CD10 1:100 
Goat polyclonal anti-TOP 1:200 
Mouse monoclonal anti-β-actin 1:1000 
 
Antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, CA (anti 
APA, anti-CD 10 and anti-TOP), anti-β-actin antibody (clone AC-15) which was 
employed as loading control was purchased from Sigma Aldrich, Dublin, Ireland. 
After 2 h incubation, membranes were washed 4 times 5 min in washing buffer, 
incubated in secondary antibodies solutions: Anti-goat IgG peroxidise antibody 
for APA and TOP and Anti-mouse IgGs peroxidase antibody for CD10 and β-
actin detection. Secondary antibodies solutions were prepared in dilution 1:4000 
in blocking buffer). Membranes were washed again 4 times 5 min. Visualisation was 
done by chemiluminescence; equal parts of two solution of Millipore 
Immobilon Western Chemiluminescent HRP substrate kit were mixed together, and 
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each membrane was covered with 1 ml of the solution for 5 min. Excess of liquid 
was drought out, membranes were placed into transparent plastic foil, 
the luminescent signal was detected on photographic film and photographs were 
developed. Presence of protein was quantified using a ChemiDoc
TM
 Bio-Rad system. 
β-actin signal was detected on the same membranes; after developing picture, 
wet membranes were immediately washed in washing buffer 2 times 10 min and 
blocked overnight at 4°C in blocking buffer while rocking. Incubations with primary 
and secondary antibodies specific for β-actin were repeated.  
 
3.6. Statistical methods 
 
Significance (p <0.05) of differences in the group mean values for TEER determined 
by one way analysis of variances (ANOVA), followed by Student-Newman-Keuls 
post-hoc tests. Each data point in figures 8-11 represents means ± S.D. (n ≥ 3) from 
3 different passages. 
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4. RESULTS 
4.1.Monolayer integrity 
 
TEER results are expressed as a mean ± S.D.  
When cultured on Transwell Clear filters, R3/1 cells at no time yielded monolayers 
with TEER values comparable to those of primary cultures of rat pneumocytes 
typically in the region of > 1500 Ω·cm2 (Cheek, Kim et al. 1989). The peak TEER 
value was recorded to be 99±17 Ω·cm2 after 5 days in culture. Variation of seeding 
density between 50,000 and 200,000/cm
2
 as well as growth under AIC conditions 
showed no significant changes of TEER of monolayers (Figure 15 and Figure 16). 
 
Figure 15: TEER of R3/1 cells under different seeding densities: 
Variation of seeding density in interval of 50,000 to 200,000 cells/cm
2
 had no impact 
on TEER values of R3/1 cell monolayers. Cells were grown in RPMI 1640 medium 
under LCC conditions. 
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Figure 16: TEER under LCC and AIC condition: Shifting from LCC to AIC 
conditions (in RPMI 1640 culture medium, seeding densities 400,000 and 800,000 
cells/cm
2
) did also not cause significant differences in TEER values. 
 
 
Withdrawal of FBS reduced the TEER to a value of 52±11 Ω·cm2 (Figure 17).  
 
Figure 17: Effect of FBS on TEER: TEER values of R3/1 cells grown under LCC 
conditions (200,000 cells/cm
2
) without FBS were reduced in comparison to cells 
cultured in the presence of FBS.  
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FBS at concentration of 20% in addition of dexamethasone (DEX, 0.1 µM) 
in the culture medium resulted in an increase of TEER by 65%. However, increased 
concentration of FBS to 20% only or addition of DEX alone caused no significant 
change in TEER values (Figure 18). 
 
Figure 18: Effect of FBS and dexamethasone on TEER: Doubled 
concentration of FBS in addition to 0.1 µM dexamethasone increased TEER values 
of R3/1 seeded in density 200,000 cells/cm
2
 under LCC conditions in DMEM - 
Ham‘s F12 medium by 65%. When only FBS concentration was increased or only 
DEX was added, no significant effect on TEER was observed. 
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RT-PCR revealed the absence of transcripts encoding E-cadherin and occludin. 
However, ZO-1 and ZO-2 mRNA transcripts were found (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 19: Representative gel of tight junction proteins in R3/1 cells: 
Representative agarose gel of the RT-PCR analysis of tight junction proteins in R3/1 
cells and rat lung tissue. Lane 2, ZO-1 in R3/1 cell line; Lane 3, ZO-1 in lung; Lane 
4, ZO-2 in R3/1 cells; Lane 5, ZO-2 in rat lung; Lane 6, E-cadherin in R3/1 cells;  
Lane 7, E-cadherin in rat lung, Lane 8, occludin in R3/1 cells; Lane 9, occludin 
in rat lung. Lanes 10 and 11 show internal standard β–actin (in R3/1 cells and rat 
lung respectively). Lane 1 contains DNA size marker. 
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IFM using a monoclonal antibody against occludin revealed the absence 
of the antigen in R3/1cells (Figure 20). R3/1 cells were processed 
for immunofluorescence microscopy using mouse monoclonal anti-occludin antibody 
and Alexa Fluor 488-labelled goat anti-mouse secondary antibody (green). DNA was 
stained with propidium iodide (red).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 20: Immunofluorescence microscopy image. No signal representing 
presence of occludin in R3/1 cells was observed. 
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4.1.Expression of proteolytic enzymes 
 
The qualitative results from the RT-PCR analysis of peptidases in R3/1 and primary 
rat pneumocytes are summarised in Table 6, pictures of PCR products separated 
by gel electrophoresis can be found in Appendix. From the range of investigated 
proteolytic enzymes, mRNA transcripts encoding aminopeptidase A and 
aminopeptidase B as well as endopeptidase 24.11 and endopeptidase 24.15 were 
detected. Transcripts for those peptidases as well as transcripts for aminopeptidase N, 
carboxypeptidase M and γ-glutamyl transferase were also present in rat alveolar 
epithelial type I cells in primary culture. In ATII primary cells genes encoding 
aminopeptidases A, N and P, carboxypeptidase M, γ-glutamyl transferase, and 
endopeptidases 24.11 and 24.15 were identified by RT-PCR. A weak signal was also 
obtained for angiotensin converting enzyme. This week expression could be caused 
by contamination with lung capillary endothelial cells. 
 
Table 6: Expression patterns of proteolytic enzymes in the R3/1 cell line as well 
as in AT I and AT II pneumocytes 
 R3/1 AT I AT II 
CPM - + + 
APA + + + 
APB + + - 
APN - + + 
APP - - + 
GGT - + + 
ACE - - (+) 
DPP IV - - - 
EP 24.11 + + + 
EP 24.15 + + + 
 
 
Western blot confirmed presence of EP 24.11(=NEP; CD10) and EP 24.15 (TOP) 
in R3/1 cells, APA was not detected (Figure 21). Homogenates of cells or serum free 
supernatant were investigated. To increase protein expression, cells were stimulated 
with phorbol myristate acetate (PMA) at concentrations of 1-100 μM. Tissue extracts 
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from rat kidneys and lungs and serum were used as positive controls. Presence 
of APB was not investigated; antibodies against rat APB are not commercially 
available. 
 
Figure 21: Representative Western blots of NEP, EP 24.15 and APA: β-
actin was used as loading control. PMA treatment did not influence 
expression of investigated enzymes. 
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5. DISCUSSION AND CONCLUSION 
 
Several cell culture models of the tracheo-bronchial epithelium have been 
characterised and are widely used for drug absorption studies. These include cell 
lines of human origin, such as Calu-3 and 16HBE14o-. Moreover, continuously 
growing airway cells with characteristics of cystic fibrosis epithelium are available. 
Although protocols for the primary culture of human tracheo-bronchial epithelial 
cells (both healthy and CF phenotypic) into well defined and differentiated confluent 
cell layers were published over 20 years ago (Gruenert, Finkbeiner et al. 1995), 
complicated maintenance, low reproducibility of absorption data, and high costs have 
prevented the application of these in vitro models at a larger scale. It should, 
nevertheless, been noted that none of the cell lines which are currently used as 
surrogates has been properly investigated with regards to their expression pattern 
of drug transporter proteins and/or metabolic enzymes. Similar investigations have 
been conducted in the area of intestinal drug disposition where the gold standard, 
the Caco-2 cell line, has been extensively and successfully compared 
to the enterocytes of the small intestine (Hilgendorf, Ahlin et al. 2007). Considering 
the potentially important role that active transport mechanisms play in the respiratory 
mucosa, it is quite surprising how little is known about the expression pattern and 
spatial distribution of transporter proteins in the lung. The extent to which cell lines 
or primary cultures can model the absorption of actively transported compounds 
remains to be shown. Existing data in this area is diverse and more systematic studies 
are underway. The evaluation of cell systems in critical in vitro-in vivo and other 
benchmarking studies will permit the rational selection of tracheo-bronchial or 
alveolar epithelial cell cultures for preclinical applications. Accordingly, the use 
of such well characterised epithelial cell systems with validated protocols 
for studying drug disposition will enhance our understanding of drug transport and 
metabolism in the lung. 
 
Major hurdles also still remain for the successful development of passageable 
alveolar type I and type II epithelial cell lines, either as separate or mixed cell types 
of ATI and ATII coexisting in a single-monolayer setting, that mimic the in vivo 
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setting. Moreover, the co-culture models of alveolar epithelium and capillary 
endothelium of the mammalian lung are in their infancy at best. With further 
refinement of such co-culture systems, additional cell types (e.g., macrophages, 
lymphocytes, dendritic cells, and/or polymorphonuclear cells) can be added 
to the culture to study various cell biology-related questions in the lung field 
(including drug metabolism and modulation of properties of lung air-blood barrier).  
 
Although most of the pioneering work in respiratory epithelial biology was based 
on isolation and culture of cells from the lungs of small laboratory animals including 
mouse, rat, and rabbit, the requirement for an organ specific cell system that is 
of human origin is paramount. However, due to the lack of availability of human 
tissue and ethical issues pertaining to the use of human tissues in certain countries, 
not much information on species differences in this specific area of cellular research 
is available yet.  
 
The advantages and limitations of using a simple culture system compared to one 
that recreates to a greater extent the epithelial structure and function in vitro should 
be considered according to the preclinical application required. This choice is 
complicated by the lack of comparative data, both between the different cell systems 
and for in vitro-in vivo correlation, upon which to base such decisions. However, no 
meaningful in vitro- in vivo correlation has been established to date for lung alveolar 
epithelial drug transport/metabolism and data reported for bronchial cell lines and 
primary models is in all cases based on intra-tracheal instillation into rodents, which 
is certainly not applicable to the in vivo situation in humans. Therefore, these 
data should be interpreted with extreme caution.  
 
Notwithstanding the difficulties and challenges surrounding various aspects 
of in vitro respiratory epithelial models, mechanistic studies of pulmonary drug 
delivery using tracheo-bronchial and alveolar mucosae are expected to provide us 
with a wealth of information in the coming years that will enable us to (1) devise 
newer and more efficient methods to treat lung-specific diseases using targeting 
approaches and (2) help improve the bioavailability of those therapeutics that yield 
very poor absorption via other routes. 
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We have shown that, R3/1 cells express some markers typical for type I pneumocytes 
(Koslowski, Barth et al. 2004) including T1α, ICAM-1, connexin-43, caveolins-1 
and -2. In contrast to primary rat pneumocytes, these cells do not form electrically 
tight monolayers. Therefore, R3/1 cells cannot be considered as a reliable in vitro 
model for alveolar absorption studies. However, our data indicate that R3/1 cells may 
be suitable for stability assays of inhaled proteins (Patton 1996). This study 
established that, although R3/1 cells express certain markers typical for type I 
pneumocytes (e.g., T1α, ICAM-1, connexin-43, caveolins-1 and -2 , their inability 
to form electrically tight monolayers prevents them from being a reliable in vitro 
model for alveolar absorption studies. 
 
Pulmonary delivery of macromolecule aerosols has been considered an attractive 
non-invasive way to overcome frequent injections. The recent termination 
of development of inhaled insulin by Nektar, Pfizer, Novo Nordisk and Eli Lilly 
might be a drawback for research in the area of insulin delivery, but other protein 
drugs may have a brighter future. However, due to their high molecular mass and 
large size, proteins may have severe difficulties to cross epithelial barriers. 
Moreover, they might be degraded by proteases and/or removed by alveolar 
macrophages, as soon as they reach the alveoli (Yamahara, Lehr et al. 1994; 
Patton 1996). To address these issues, in vitro models of alveolar epithelium can be 
useful in predicting the fate of peptides and proteins administered to the lung 
(Yamahara, Lehr et al. 1994; Williams 2003; Bur, Huwer et al. 2006). Hence, it was 
important and relevant to compare the protease expression pattern of R3/1 cells with 
primary rat pneumocytes in vitro as this continuous cell line potentially could enable 
in vitro screening of enzymatic stability of proteins and peptides. From the range 
of proteolytic enzymes investigated in our study APN, CPM and GGT were 
differently expressed in R3/1 cells and ATI-like cells in primary culture, whereas 
CPM, APB, APN, APP, GGT and ACE were differently expressed in R3/1 and ATII 
cells.  
 
The distribution of proteolytic enzymes in ATI vs. ATII cells in vivo as well as 
in vitro in different cell types/cell lines of lung epithelial origin has not been 
extensively investigated. The transdifferentiation from ATII to ATI-like cells in vitro 
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has been reported to go along with increased CPM activity and a decrease of DPP IV 
expression (Nagae, Abe et al. 1993; Forbes, Wilson et al. 1999; Williams 2003).  
 
In contrast, presence of GGT has been controversial. Some reports describe 
the enzyme as a typical feature of ATI cells (Ingbar, Hepler et al. 1995) while others 
suggests GGT to be characteristic for the ATII phenotype (Joyce-Brady, Takahashi 
et al. 1994). In our study we found CPM and GGT in both ATI-like cells and freshly 
isolated ATII cells RT-PCR, while DPP IV was not detectable. The activity of ACE 
was first reported by Forbes and co-workers to be associated with the ATII 
phenotype and this was confirmed in our study. However, it cannot be completely 
ruled out this signal might have been generated by contaminating endothelial cells 
in the ATII population in both studies (Forbes, Wilson et al. 1999). Investigations 
of catabolic peptidases in the A549 cell line have confirmed the presence of CPM, 
APN, DPP IV and EP 24.11 (Forbes, Wilson et al. 1999). This expression pattern 
resembles neither ATI nor ATII cells. In contrast, the pattern of proteolytic enzymes 
found in the R3/1 cell line showed more similarities to ATI than ATII pneumocytes. 
Since ATI cells cover the vast majority of the pulmonary epithelial surface, it can be 
suggested that this cell type might be of most interest when it comes to protein 
absorption and degradation.  
 
It can be concluded that R3/1 cells are unlikely to be used as an in vitro screening 
model for alveolar absorption. However, the cells are suitable for an in vitro 
screening model for protein and peptide stability studies. 
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8. SUMMARY 
 
Buněčná řada R3/1 odvozená z krysích embryí, vykazuje několik fenotypových znaků 
vlastních buňkám alveolárního epitelu I. řádu. Cílem této práce bylo dále popsat vlastnosti 
R3/1 buněčné linie vzhledem k jejímu případnému využití jako in vitro drug 
disposition model, tj. model popisující veškeré procesy zahrnující absorpci, distribuci, 
metabolismus a exkreci léčiva do organismu. R3/1 buňky byly kultivovány na Traswell 
filtrech a transepitheliální elektrický odpor (TEER) byl měřěn jako parametr integrity 
buněčných vrstev. Přítomnost proteinů důležitých pro vytvoření funkčních buněčných 
spojení (tight junction, TJ) - E-cadherinu, occludinu a proteinů ZO-1 a ZO-2 
byla analyzována na úrovni mRNA pomocí polymerázové řetězové reakce s reverzní 
transkripcí (RT-PCR) a na úrovni antigenu pomocí imunofluorescenční mikroskopie (IFM). 
Dále byla sledována přítomnost katabolických peptidáz, konkrétně karboxypeptidázy M, 
aminopeptidáz A, B, N a P, γ-glutamyltransferázy, dipeptidylpeptidázy IV, 
angiotensin konvertujícího enzymu a endopeptidáz 24.11 a 24.15. Zároveň s R3/1 buňkami 
byly tyto peptidázy stanoveny v primárních kulturách alveolárního epitelu potkanů 
a výsledky byly porovnány.  
Hodnoty TEER dosáhly maximální hodnoty ~99±17 Ω•cm2 pátého dne kultivace, obohacení 
živného media o dexametazon (v koncentraci 0.1 µM) společně s dvojnásobným množstvím 
séra v médiu (zvýšení z 10 na 20 %) mělo za výsledek vzestup TEER o 65 %. I přesto se 
TEER R3/1 buněk nepřiblížil k hodnotám, které vykazovaly primární kultury krysích 
pneumocytů. 
Výsledky RT-PCR odhalily absenci transkriptů kódujících E-cadherin and occludin, oproti 
tomu byly nalezeny mRNA transkripty pro ZO-1 a -2. IFM používající monoklonální 
protilátku proti occludinu potvrdila nepřítomnost antigenu v R3/1 buňkách. Ze 
spektra proteolytických enzymů analyzovaných metodou RT-PCR byla zjištěna přítomnost 
mRNA transkriptů pro aminopeptidázy A a B a rovněž pro endopeptidázy 24.11 a 24.15. Při 
porovnání peptidáz přítomných v R3/1 buněčné řadě s peptidázami nalezenými v krysích 
pneumocytech I. a II. řádu je patrná podobnost R3/1 buněk s epitelem I. řádu. 
Ačkoli R3/1 buněčná řada disponuje několika charakteristickými znaky typickými pro 
alveolární epiteliální buňky I. řádu, jako je T1α, ICAM-1, connexin-43, caveoliny-1 a -2, 
není schopná vytvářet dostatečně pevná TJ a tudíž nemůže být vhodným in vitro modelem 
pro studování absorpce léčiv. Tato buněčná linie může najít uplatnění jako model pro 
stabilitní studie inhalovaných léčiv – peptidů. 
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The rat cell line R3/1 displays several phenotypical features of alveolar epithelial type I cells. 
In order to characterise the cell line as an in vitro model for drug disposition studies, R3/1 
cells were cultured on Transwell filters and the transepithelial electrical resistance (TEER) 
was measured as a parameter for the integrity of cell layers. Presence of cell junctional 
proteins (i.e., E-cadherin, occludin, ZO-1 and ZO-2) was studied on mRNA (by reverse 
transcriptase-polymerase chain reaction, RT-PCR) and antigen level (by 
immunofluorescence microscopy, IFM). Moreover, the expression pattern of catabolic 
peptidases (carboxypeptidase M, aminopeptidases A, B, N and P, γ-glutamyltransferase, 
dipeptidylpeptidase IV, angiotensin-converting enzyme, and endopeptidases 24.11 and 
24.15) was analysed in R3/1 cells and compared to rat alveolar epithelial I-like cells 
in primary culture.  
 
TEER values were peaking at ~99±17 Ω•cm2 after 5 days in culture. Addition of 0.1 µM 
dexamethasone together with foetal bovine serum at 20% increased TEER by 65%. 
However, none of culture conditions used in our study yielded monolayers with TEER 
values comparable to those of primary cultures of rat pneumocytes. RT-PCR revealed 
the absence of transcripts encoding for E-cadherin and occludin. However, ZO-1 and -2 
mRNA transcripts were found. IFM using a monoclonal antibody against occludin confirmed 
the absence of the antigen in R3/1 cells. From the range of investigated proteolytic enzymes, 
mRNA transcripts encoding aminopeptidases A and B as well as endopeptidases 24.11 and 
24.15 were detected; a pattern similar to rat alveolar epithelial I-like cells in primary culture. 
 
Although R3/1 cells express certain markers typical for type I pneumocytes (e.g., T1α, 
ICAM-1, connexin-43, caveolins-1 and -2), their inability to form electrically tight 
monolayers prevents them from being used as an in vitro model for alveolar absorption. 
The R3/1 cell line might be useful for stability assays of inhaled proteins. 
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9. APPENDIX 
 
RT-PCR products separated by agarose gel electrophoresis.  
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